For children < 30 kg
LAMIVIR-S BABY/JUNIOR should be administered to patients who are initiating therapy with Triomune Baby/Junior , as per the schedule given in Table 2 below. This is to facilitate the 14-day lead-in dosing for nevirapine.
Table 2: Lead-in dosage schedule for children weighing < 30 kg
Weight range |
Schedule |
3-<6 kg |
1 tablet Triomune Baby in the morning
+
1 tablet Lamivir-S Baby in the evening |
6-<10 kg |
1 ½ tablets Triomune Baby in the morning
+
1½ tablets Lamivir-S Baby in the evening |
10-<15 kg |
1 tablet Triomune Junior in the morning
+
1 tablet Lamivir-S Junior in the evening |
15-<20 kg |
1 tablet Triomune Junior in the morning
+
1½ tablets Lamivir-S Junior in the evening |
20-<25 kg |
1½ tablets Triomune Junior in the morning
+
1½ tablets Lamivir-S Junior in the evening |
25-<30 kg |
2 tablets Triomune Junior in the morning
+
2 tablets Lamivir-S Junior in the evening |
Following this 14-day lead-in dose, treatment with Triomune Baby/Junior twice daily may be carried out in the absence of any hypersensitivity reactions to nevirapine, such as rash, liver function test abnormalities, given as per Table 3.
Table 3: Chronic dosage schedule for Triomune Baby/Junior
Weight range |
Schedule |
3-<6 kg |
1 tablet Triomune Baby bid |
6-<10 kg |
1½ tablets Triomune Baby bid |
10-<15 kg |
1 tablet Triomune Junior bid |
15-<20 kg |
1 tablet Triomune Junior in the morning and
1 ½ tablets Triomune Junior in the evening |
20-<25 kg |
1½ tablets Triomune Junior bid |
25-<30 kg |
2 tablets Triomune Junior bid |
For children ≥ 30 kg
For children weighing ≥ 30 kg, Lamivir-S 30 should be administered to patients who are initiating therapy with Triomune-30 , as per the schedule given in Table 4 . This is to be followed by Triomune-30 twice daily in the absence of any hypersensitivity reactions as given in Table 5 .
Table 4: Lead-in dosage schedule for children weighing ≥ 30 kg
Weight range |
Schedule |
≥ 30kg |
1 tablet Lamivir-S 30 in the morning + 1 tablet Triomune -30 in the evening |
Table 5: Chronic dosage schedule for Triomune-30
Weight range |
Schedule |
≥ 30 kg |
1 tablet Triomune-30 bid |
Monitoring of patients
Stavudine
Patients should be monitored for the development of peripheral neuropathy, which is usually manifested by numbness, tingling or pain in the feet or hands. These symptoms may be difficult to detect in young children. If these symptoms develop during treatment, stavudine therapy should be interrupted. Symptoms may resolve if therapy is withdrawn promptly. In some cases, symptoms may worsen temporarily following discontinuation of therapy. If symptoms resolve completely, patients may tolerate resumption of treatment at one half the recommended dose.
|
